The FDA announced late last year that it was considering pulling “not effective” nasal decongestants — including DayQuil, Sudafed and Mucinex — from stores. The agency’s Nonprescription ...

Women across social media platforms share their journeys of using Mucinex for fertility enhancement, spurring discussions ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

The nasal spray can be given to people who haven’t seen improvements to their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Since using black market nasal tanning spray, Harper has had facial flushes ... but also those posed by undeclared ingredients or other potential contaminants. Photo shows A woman sunbaking ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

But there are specific kinds that are best: “Cough medicines that contain guaifenesin and dextromethorphan should be okay for a short time,” says Meleen Chuang, MD, the chief of obstetrics and ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...